An interventional study of Silver sulfadiazine 1%cream and Alovera gel in Superficial and Superficial Partial Thickness Burns, sponsored by University of Child Health Sciences and Children's Hospital, Lahore. Completed at 1 site in Pakistan. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by University of Child Health Sciences and Children's Hospital, Lahore · Not applicable, Interventional, and Treatment
Among 17 studies in Burns with a site in Pakistan — 4 open to participants now, 6 under way, none of them phase 3. Burns · Pakistan.
Among the 17 studies in Burns with a site in Pakistan, this one is the 9th largest by enrollment, is one of 3 that started in 2025, is one of 14 with no phase, and was the 16th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →4 of the 17 studies in Burns with a site in Pakistan are open now. Recruiting first, the newest first:
Patel Hospital, Pakistan · Sites in Pakistan
King Edward Medical University · Sites in Pakistan
Ages 18–60
abdul mateen · Sites in Pakistan
Ages 5–13
Dr Muhammad Naveed Shahzad · Sites in Pakistan
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 84 Burns studies recruiting now, 38 (45%) set no upper age limit and 37 (44%) stop at 75 or younger; 17 take children under 18; 9 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 60 across the 17 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 8 most frequent:
University of Child Health Sciences and Children's Hospital, Lahore is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
University of Child Health Sciences and Children's Hospital, Lahore has 1 study filed under Burns — fewer than ten, so there is no comparison to draw.
1 of the studies in Burns with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07870239abdul mateenComparison of Topical Antibiotics Versus Systemic Antibiotics in Preventing Burn Wound Infection in Pediatric Burn Patients | 2027-05-05 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Burns with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective randomized controlled study aims to compare the effectiveness of Aloe vera gel versus 1% silver sulfadiazine in the treatment of superficial and superficial partial-thickness burns in the pediatric population. Burn injuries are among the most common causes of morbidity in children, and optimal topical treatment is important for pain control, prevention of infection, and rapid wound healing.
Pediatric patients presenting with superficial and superficial partial-thickness burns will be enrolled and allocated into two treatment groups. One group will receive topical Aloe vera gel, while the other group will receive 1% silver sulfadiazine dressing according to standard burn care protocols. Patients will be followed regularly to assess wound healing progress, pain, infection rate, duration of healing, frequency of dressing changes, and any treatment-related complications. The primary outcome will be time to complete wound healing, while secondary outcomes will include pain score, infection rate, hospital stay, and scar formation.
Burn injuries are a significant cause of morbidity among the pediatric population and require effective topical therapy to promote wound healing, prevent infection, reduce pain, and minimize treatment cost. Silver sulfadiazine 1% cream is commonly used as a standard topical antimicrobial agent for superficial burns; however, delayed wound healing and frequent dressing requirements have encouraged the search for alternative therapies. Aloe vera has demonstrated anti-inflammatory, antimicrobial, soothing, and wound-healing properties in previous studies and may serve as an effective and economical alternative in burn management.
This randomized controlled trial will be conducted at The Children's Hospital \& Institute of Child Health Lahore over a duration of one year. A total of 60 pediatric patients aged 1 to 18 years presenting with superficial and superficial partial-thickness burns involving 1% to 25% total body surface area (TBSA) will be enrolled in the study. Patients will be randomly allocated into two groups by coin toss/lottery method. One group will receive topical Aloe vera gel dressing, while the second group will receive 1% silver sulfadiazine dressing. Dressings will be applied three times daily according to institutional burn care protocol.
Patients will be followed for a period of 14 days to assess treatment outcomes. The primary outcome measure will be the degree and rate of re-epithelialization of burn wounds. Secondary outcome measures will include pain relief, infection rate, and cost effectiveness of treatment. Patients with burns deeper than superficial partial-thickness burns, including deep second-degree and third-degree burns, as well as patients requiring surgical intervention or presenting with major associated comorbidities, will be excluded from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alovera gel applied 3 times daily until complete repithelization
Other: Alovera gel
Silver sulfadiazine applied 3 times daily until complete repithelization
Drug: Silver sulfadiazine 1%cream
Silver sulfadiazine applied 3 times daily until complete repithelization
Alovera gel applied 3 times daily until complete repithelization
Degree of repithelization
The primary outcome is the degree and rate of re-epithelialization of superficial and superficial partial-thickness burn wounds in pediatric patients. Wound healing will be assessed clinically by measuring percentage of wound closure and epithelial regeneration over a follow-up period of 14 days or until complete healing, whichever occurs earlier
Time frame: 14 days
Pain relief
Pain relief will be assessed using age-appropriate pain scoring systems (FLACC scale for younger children and Visual Analogue Scale for older children). Changes in pain scores will be recorded before and after treatment during the 14-day follow-up period.
Time frame: 14 days
Wound Infection
The incidence of wound infection will be assessed clinically based on signs such as erythema, purulent discharge, increased pain, or fever during the treatment period
Time frame: 14 days
Cost effectiveness
Cost effectiveness will be evaluated by comparing the total cost of treatment in both groups, including dressing materials, frequency of dressing changes, and overall management expenses during the study period.
Time frame: 14 days
Plan to share: No — Pediatric patient data is sensitive Requires strict ethical approval for sharing Most single-center academic RCTs in Pakistan do not share IPD publicly
Ran from Feb 2025 to primary completion in Mar 2026, 12 months.
Of 210 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's 12 months is below that.
Counting every sponsor, half of 239 studies reached it within 15 months; a quarter within 6 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Child Health Sciences and Children's Hospital, Lahore